Jun 17, 2022, 09:10 AM by

Jun 17, 2022, 09:08 AM by

YewMaker and Connect in Pharma announce today that the winners of the new Sustainable Medicines Packaging Awards will be announced at an in-person champagne ceremony at the Connect In Pharma event in Geneva on 14 September 2022. The new awards, run by sustainable healthcare pioneers YewMaker, will showcase and celebrate sustainable innovations revolutionising pharmaceutical packaging, with Gold, Silver and Bronze award winners under two categories.

Jun 17, 2022, 01:00 AM by User Not Found

Bio-IT World | Recent advances in the commercialization of neuroscience data acquisition technology have enabled a quickly growing collection of massive brain activity and behavioral datasets. Within the data lie exciting promises of solving how the brain generates behavior, and how it might be better healed when diseased or disturbed. But interpreting these large, high-dimensional datasets isn’t easy. We need modern, collaborative solutions that help scale data management, analysis, and knowledge sharing.

Jun 16, 2022, 09:39 AM by

Earlier this month, the management of Alfa Chemistry announced the launch of varieties of chemical fluorophores for researchers worldwide. Those newly released fluorophores, including BODIPY fluorophores, cyanine fluorophores, rhodamine fluorophores, and fluorescein fluorophores, can be widely used for bioanalysis, environmental monitoring, clinical diagnosis, fluorescence staining, as well as other application scenarios.

Jun 16, 2022, 01:00 AM by User Not Found

Bio-IT World | “Thirty to 40% of clinical trial costs are associated with actually just the manual retyping of [EHR] data [into the clinical trial system], and it leads to reporting delays and a number of other inefficiencies,” Adam Asare, chief data officer at the Quantum Leap Healthcare Collaborative/UCSF, told the Bio-IT World Conference & Expo audience last month. Asare shared a solution to that problem: a collaboration with OpenClinica that won the team a Bio-IT World Innovative Practices Award.

Jun 15, 2022, 09:29 AM by

Creative Biogene recently developed the C. elegans lysis/DNA extraction kits (CDC-k108) are now available to worldwide clients and partners.

Jun 15, 2022, 09:29 AM by

Creative Biogene announced the release of Bacillus subtilis cultivation service using flexible fermentation and cultivation strategies to help customers in obtaining high-yield and bioactive B. subtilis bioproducts.

Jun 15, 2022, 09:29 AM by

MOBILion Systems Inc. delivers technical presentations and unveils new applications areas for its HRIM instrument, MOBIE, at ASMS 2022.

Jun 15, 2022, 09:29 AM by

mdgroup appoints LaQuinta Jernigan as Chief Operating Officer Executive leadership appointment to drive seamless client experiences in patient- servicing and digitally enabled clinical trials

Jun 15, 2022, 01:00 AM by User Not Found

Bio-IT World | While the field of targeted protein degradation (TPD) continues its rapid expansion, with multiple TPD drugs now in clinical trials, researchers in Australia are jumping in at an earlier stage with “tag technology” to ensure the disease protein is worth designing a drug against in the first place. Their work—an extension of other tag-targeting protein degradation technologies—gives researchers the wherewithal to ask if, “the juice is worth the squeeze,” according to Rebecca Feltham, Ph.D., laboratory head in the Ubiquitin Signalling Division of the Walter and Eliza Hall Institute.

Jun 14, 2022, 09:29 AM by

Jun 14, 2022, 01:00 AM by User Not Found

Bio-IT World | A significantly heightened risk of breast cancer has two well-known culprits—mutations to the tumor suppressor genes BRCA1 and BRCA2—but more than 40% of the time they are black-box “variants of uncertain significance.” Using a new data-sharing innovation known as federated analysis, however, an international team of researchers has categorized 16 of these uncertain variants as benign or likely benign so their carriers may be able to have their clinical risk of disease managed properly and avoid the risk of invasive and irrevocable surgeries.

Jun 13, 2022, 09:41 AM by

As per Persistence Market Research’s latest industry analysis, the global medical wellness market was valued at over US$ 1 Tn in 2020, and is expected to exhibit a CAGR of 14.1% over the forecast period (2021-2031).

Jun 10, 2022, 09:03 AM by

Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.

Jun 10, 2022, 09:03 AM by

mdgroup recognised as one of the UK's fastest-growing private companies 9 June 2022 - Bracknell, UK: mdgroup has been shortlisted as one of the UK's fastest-growing private companies in the inaugural Sunday Times 100 ranking.

Jun 9, 2022, 09:13 AM by

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer

Jun 9, 2022, 09:13 AM by

CAMBRIDGE, UK, 08 June 2022: Optibrium™, a developer of software for drug discovery, today announced the expansion of its UK headquarters with a move to larger office premises on Cambridge Innovation Park North. The new facilities accommodate Optibrium's accelerated growth and ongoing recruitment efforts to support the continued success and development of the company's innovative technology focused on improving the efficiency and productivity of the drug discovery process.

Jun 9, 2022, 09:12 AM by

Medcura, Inc., a commercial-stage life science and medical device company, has appointed James (Jim) Buck as Chief Executive Officer (CEO). A globally connected leader, Buck has been serving as Director at Medcura since 2018 and now fully steps into the CEO role with more than 25 years of highly relevant career experiences.

Jun 9, 2022, 01:00 AM by User Not Found

Bio-IT World | Over the past two years, Stan Gloss, founding partner at BioTeam, has been sitting down with leaders in pharma and biotech for our Trends from the Trenches column and—more recently—the Trends from the Trenches podcast. They have been wide-ranging conversations covering everything from digital transformation at big pharma to All of Us and population genomics, data-driven cancer genomics to AI/ML models in drug discovery.

Jun 8, 2022, 09:18 AM by